|

Germline Testing for Predisposition to Myeloid Malignancies

RECRUITINGN/ASponsored by Christopher Reilly
Actively Recruiting
PhaseN/A
SponsorChristopher Reilly
Started2025-11-10
Est. completion2030-04-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07112287

Summary

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age of 18 years or older
* Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
* Ability to understand and provide a signed and completed consent document in English.

Exclusion Criteria:

* Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.
* Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies

Conditions4

CancerGenetic Predisposition to DiseaseMyeloid Hematological MalignanciesMyeloid Malignancy

Locations1 site

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Christopher R Reilly, MD407-443-6243christopherr_reilly@dfci.harvard.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.